Meri‐Sisko Vuoristo

High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma

Johanna Nikkola, Pia Vihinen, Meri‐Sisko Vuoristo et al. · Clinical Cancer Research · 2005 · 195 citations · Full text

A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma

Pia Vihinen, Micaela Hernberg, Meri‐Sisko Vuoristo et al. · Melanoma Research · 2010 · 56 citations

Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-?? in patients with advanced melanoma

Meri‐Sisko Vuoristo, Marjo Hahka‐Kemppinen, L.-M. Parvinen et al. · Melanoma Research · 2005 · 34 citations

Oncology, Recombinant Interferon-, Health Sciences +14

Serum VEGF-C is associated with metastatic site in patients with malignant melanoma

Pia Vihinen, Johanna Hilli, Meri‐Sisko Vuoristo et al. · Acta Oncologica · 2006 · 31 citations · Full text

Tumor Biology, Medicine, Melanoma +13

Serum angiogenin levels predict treatment response in patients with stage IV melanoma

Pia Vihinen, Minna Kallioinen, Meri‐Sisko Vuoristo et al. · Clinical & Experimental Metastasis · 2007 · 21 citations

Medicine, Melanoma, Treatment Response +7